Cidara Therapeutics宣布三期关键临床试验首批受试者开始接受CD388治疗,该试验旨在评估CD388预防高危人群季节性流感的效果。
Cidara Therapeutics宣布三期关键临床试验首批受试者开始接受CD388治疗,该试验旨在评估CD388预防高危人群季节性流感的效果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.